April.2022-March.2023

13/3/2023

Announcement regarding Development of New Cancer Gene Panel Test at Our Subsidiary Company, Cancer Precision Medicine, Inc.
9/3/2023

Announcement regarding termination of out-licensing contract and agreement to transfer patent rights of antibodies between our subsidiary company
31/10/2022

Announcement of Research for New Compounds

back to top